drugset / Trial / NCT02560272
Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine,Freeze-dried
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study will evaluate the safety and immunogenicity of a haemophilus influenzae type b conjugate vaccine (Hib) in Healthy Children 2 Months to 5 Years of Age who have not been previously immunized with a Hib vaccine. Children 2 to 5 months of age will receive 3 doses of Hib vaccine, Children 6 to 11 months of age will receive 2 doses of Hib vaccine, Children 1 to 5 years of age will receive 1 dose of Hib vaccine, with each dose given approximately 1 month apart.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-12
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ActHIB | Vaccine | 0.5 ml | Intramuscular |
| Subject | Minhai-HIB | Vaccine | 0.5 ml | Intramuscular |